Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (121-130 of 210) with videos related to

Pageof 21
Sort By:
Oncology|October 3, 2018
Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in FranceLaurence Bigay-Gamé, Suzanna Bota, Laurent Greillier, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2025
Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score MatchingEtienne Cedoz, Antonin Levy, Isabelle Martel-Lafay, et al.
Expert Review of Anticancer Therapy|September 25, 2014
Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapyStefan Walzer, Christos Chouaid, Johanna Lister, et al.
Lung Cancer (Amsterdam, Netherlands)|September 28, 2021
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study)Jean-Bernard Auliac, Isabelle Monnet, Acya Bizieux, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapyRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
Intensive Care Medicine|November 5, 2014
Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care unitsAnne-Claire Toffart, Xavier Dhalluin, Nicolas Girard, et al.
Chest|April 8, 2009
Role for interleukin-6 in COPD-related pulmonary hypertensionAri Chaouat, Laurent Savale, Christos Chouaid, et al.
Targeted Oncology|August 2, 2017
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study)Jean-Bernard Auliac, Isabelle Monnet, Catherine Dubos-Arvis, et al.
Future Oncology (London, England)|June 22, 2021
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50Renaud Descourt, Christos Chouaid, Maurice Pérol, et al.
Occupational and Environmental Medicine|June 26, 2024
Relationships between asbestos exposure and pleural plaques: dose and time effects using fractional polynomialsMorgane Menant, Ilyes Benlala, Isabelle Thaon, et al.
Pageof 21

Showing results (121-130 of 210) with videos related to

Sort By:
Pageof 21
Oncology|October 3, 2018
Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in FranceLaurence Bigay-Gamé, Suzanna Bota, Laurent Greillier, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2025
Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score MatchingEtienne Cedoz, Antonin Levy, Isabelle Martel-Lafay, et al.
Expert Review of Anticancer Therapy|September 25, 2014
Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapyStefan Walzer, Christos Chouaid, Johanna Lister, et al.
Lung Cancer (Amsterdam, Netherlands)|September 28, 2021
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study)Jean-Bernard Auliac, Isabelle Monnet, Acya Bizieux, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapyRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
Intensive Care Medicine|November 5, 2014
Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care unitsAnne-Claire Toffart, Xavier Dhalluin, Nicolas Girard, et al.
Chest|April 8, 2009
Role for interleukin-6 in COPD-related pulmonary hypertensionAri Chaouat, Laurent Savale, Christos Chouaid, et al.
Targeted Oncology|August 2, 2017
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study)Jean-Bernard Auliac, Isabelle Monnet, Catherine Dubos-Arvis, et al.
Future Oncology (London, England)|June 22, 2021
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50Renaud Descourt, Christos Chouaid, Maurice Pérol, et al.
Occupational and Environmental Medicine|June 26, 2024
Relationships between asbestos exposure and pleural plaques: dose and time effects using fractional polynomialsMorgane Menant, Ilyes Benlala, Isabelle Thaon, et al.
Pageof 21